6 citations
,
July 2025 in “Cancer Medicine” ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.
6 citations
,
January 1996 in “Endocrine-related Cancer” Combining flutamide and finasteride can reduce prostate weight and tumor growth, potentially benefiting treatments needing optimal DHT inhibition.
6 citations
,
November 2020 in “JAAD Case Reports” Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
2 citations
,
January 2016 in “Sarcoma” Inducing survivin in normal tissues can protect against radiation damage.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
72 citations
,
November 2012 in “PloS one” The protein folliculin, involved in a rare disease, works with another protein to control how cells stick together and their organization, and changes in this interaction can lead to disease symptoms.
June 2018 in “The Journal of Sexual Medicine” Finasteride helps female-pattern hair loss.
May 2026 in “Journal of Clinical Oncology” Later line chemotherapy causes severe side effects, impacting quality of life, but patients continue treatment to extend life and stay connected with loved ones.
April 2024 in “Authorea (Authorea)” Stopping heptaminol medication reversed hair color loss in a patient on dialysis.
43 citations
,
January 2014 in “Indian Journal of Dermatology” EGFR inhibitors can cause skin issues like acne and dryness, but these can be managed without stopping treatment.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
January 2024 in “Clinical and Experimental Dermatology” Baricitinib helps treat severe hair loss in people over 65.
5 citations
,
January 2004 in “Biochimie” Arsenic trioxide effectively treats APL, improving survival rates despite its toxicity.
11 citations
,
October 2019 in “Cancers” Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
5 citations
,
January 2023 in “IDCases” Albendazole and praziquantel can cause severe side effects, especially with prolonged use or liver issues.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
1 citations
,
January 2026 in “International Journal of Dermatology” Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
March 2025 in “OncoTargets and Therapy” A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.
February 2025 in “Journal of Pharmaceutical and Health Research” Arumanis mango rind extract and its fractions can kill breast cancer cells, especially the ethanol extract and ethyl acetate fraction.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Rituximab can cause skin issues, but baricitinib may help improve them.
5 citations
,
July 2007 in “PubMed” An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.
Loss of the p53 gene alone causes tumors, and losing both p53 and Rb genes speeds up aggressive skin cancer.